Three-Dimensional Reconstructed Bone Marrow Matrix Culture Improves the Viability of Primary Myeloma Cells In-Vitro via a STAT3-Dependent Mechanism
Open Access
- 8 June 2021
- journal article
- research article
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 43 (1) , 313-323
Abstract
Primary myeloma (PM) cells are short-lived in conventional culture, which limited their usefulness as a study model. Here, we evaluated if three-dimensional (3D) culture can significantly prolong the longevity of PM cells in-vitro. We employed a previously established 3D model for culture of bone marrow mononuclear cells isolated from 15 patients. We assessed the proportion of PM cells, viability and proliferation using CD38 staining, trypan blue exclusion assays and carboxy fluorescein succinimidyl ester (CFSE) staining, respectively. We observed significantly more CD38+ viable cells in 3D than in conventional culture (65% vs. 25%, p = 0.006) on day 3. CFSE staining showed no significant difference in cell proliferation between the two culture systems. Moreover, we found that PM cells in 3D culture are more STAT3 active by measure of pSTAT3 staining (66% vs. 10%, p = 0.008). Treatment of IL6, a STAT3 activator significantly increased CD38+ cell viability (41% to 68%, p = 0.021). In comparison, inhibition of STAT3 with Stattic significantly decreased PM cell viability in 3D culture (38% to 17% p = 0.010). Neither IL6 nor Stattic affected the PM cell viability in conventional culture. This study suggests that 3D culture can significantly improve the longevity of PM cells in-vitro, and STAT3 activation can further improve their viability.Keywords
This publication has 34 references indexed in Scilit:
- Investigation of Cross-Contamination and Misidentification of 278 Widely Used Tumor Cell LinesPLOS ONE, 2017
- Multiple myeloma cell lines and primary tumors proteome: protein biosynthesis and Immune system as potential therapeutic targetsGenes & Cancer, 2015
- Deciphering the Correlation between Breast Tumor Samples and Cell Lines by Integrating Copy Number Changes and Gene Expression ProfilesBioMed Research International, 2015
- Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and BortezomibClinical Cancer Research, 2015
- Pathogenesis beyond the cancer clone(s) in multiple myelomaBlood, 2015
- Cell-line authentication demystifiedNature Methods, 2014
- The Clinical Relevance of Cancer Cell LinesJNCI: Journal of the National Cancer Institute, 2013
- Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumabHaematologica, 2010
- Genomic Changes and Gene Expression Profiles Reveal That Established Glioma Cell Lines Are Poorly Representative of Primary Human GliomasMolecular Cancer Research, 2008
- Characterization of in vitro growth of multiple myeloma cellsExperimental Hematology, 2007